Shares of argenx ARGX fell 3.2% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share were down 60.08% year over year to ($4.21), which missed the estimate of ($3.19).
Revenue of $7,587,000 declined by 60.98% year over year, which missed the estimate of $19,310,000.
Looking Ahead
argenx hasn't issued any earnings guidance for the time being.
argenx hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Mar 04, 2021
Time: 08:30 AM
ET Webcast URL: https://www.argenx.com/investors/events-presentations#
Price Action
52-week high: $382.15
Company's 52-week low was at $103.75
Price action over last quarter: Up 22.20%
Company Profile
argenx SE is a clinical stage biotechnology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Its product pipeline includes product candidates such as ARGX-111, ARGX-109, ARGX-115, ARGX-112, and others. The company operates in the Netherlands, Germany, Denmark, Belgium, Switzerland, the United States, and Luxembourg. It derives the majority of its revenues from Switzerland.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
